{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T18:32:47Z","timestamp":1765823567107,"version":"3.48.0"},"reference-count":74,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"unspecified","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014103","name":"Key Research and Development Program of Shandong Province","doi-asserted-by":"crossref","award":["No. 2017CXGC1215"],"award-info":[{"award-number":["No. 2017CXGC1215"]}],"id":[{"id":"10.13039\/100014103","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81570485 and No. 81770538"],"award-info":[{"award-number":["No. 81570485 and No. 81770538"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2020,8,22]]},"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      Furazolidone containing regimen is effectivefor\n                      <jats:italic>Helicobacter pylori<\/jats:italic>\n                      (\n                      <jats:italic>H. pylori<\/jats:italic>\n                      ) infection, but its safetyremains controversial. To assess the safety of furazolidone containing regimenin\n                      <jats:italic>H. pylori<\/jats:italic>\n                      infection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A systematic review and meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>PubMed, Embase, Cochrane Library, Web of Science and Scopus databases were systematically searched for eligible randomised controlled trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria<\/jats:title>\n                    <jats:p>Studies comparing furazolidone with non-furazolidone-containing regimen, variable durations or doses of furazolidone were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data extraction and synthesis<\/jats:title>\n                    <jats:p>Two reviewers independently selected studies and extracted data. Primary outcomes were the risk of total adverse events (AEs), serious AEs and severe AEs, expressed as relative risk (RR) with 95% CI. Secondary outcomes contained the incidence of individual adverse symptoms, AE-related treatment discontinuation and compliance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-six articles were identified from 2039 searched records, of which 14 studies (n=2540) compared furazolidone with other antibiotics. The eradication rates of furazolidone-containing regimen were higher than those of other antibiotics in both intention-to-treat (RR 1.06, 95% CI 1.01 to 1.12) and per-protocol analysis (RR 1.05, 95% CI 1.00 to 1.10). Only two serious AEs were reported in furazolidone group (2\/1221, 0.16%). No significant increased risk was observed for the incidence of total AEs (RR 1.04, 95% CI 0.89 to 1.21) and severe AEs (RR 1.81, 95% CI 0.91 to 3.60). Twelve studies (n=3139) compared different durations of furazolidone, and four studies (n=343) assessed variable doses. Elevated risk of total AEs and severe AEs were only found in a high daily dose of furazolidone rather than prolonged duration. The incidence of AE-related treatment discontinuation and compliance of patients were all similar, irrespective of dose and duration adjustments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Furazolidone-containing regimen has a similar risk of AEs and compliance as non-furazolidone-containing regimen. A low daily dose of 200 mg is well-tolerated for 14 day regimen and should be first considered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42019137247<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-037375","type":"journal-article","created":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T17:35:22Z","timestamp":1603128922000},"page":"e037375","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":21,"title":["Safety of furazolidone-containing regimen in\n                    <i>Helicobacter pylori<\/i>\n                    infection: a systematic review and meta-analysis"],"prefix":"10.1136","volume":"10","author":[{"given":"Chao-ran","family":"Ji","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shangdong, China"},{"name":"Laboratory of Translational Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shangdong, China"},{"name":"Laboratory of Translational Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue-yue","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shangdong, China"},{"name":"Laboratory of Translational Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan-guo","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Hong Kong, Hong Kong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-yan","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shangdong, China"},{"name":"Laboratory of Translational Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shangdong, China"},{"name":"Laboratory of Translational Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9556-8771","authenticated-orcid":false,"given":"Xiuli","family":"Zuo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shangdong, China"},{"name":"Laboratory of Translational Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,10,19]]},"reference":[{"key":"2025121510274989000_10.10.e037375.1","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/apt.14561","article-title":"Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection","volume":"47","author":"Zamani","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121510274989000_10.10.e037375.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc703"},{"key":"2025121510274989000_10.10.e037375.3","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28999"},{"key":"2025121510274989000_10.10.e037375.4","article-title":"Helicobacter pylori eradication for the prevention of gastric neoplasia","author":"Ford","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121510274989000_10.10.e037375.5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.01.028"},{"key":"2025121510274989000_10.10.e037375.6","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13497"},{"key":"2025121510274989000_10.10.e037375.7","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.192757"},{"key":"2025121510274989000_10.10.e037375.8","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.07.007"},{"key":"2025121510274989000_10.10.e037375.9","doi-asserted-by":"crossref","first-page":"6920","DOI":"10.3748\/wjg.v23.i37.6920","article-title":"Resistance of Helicobacter pylori to furazolidone and levofloxacin: A viewpoint","volume":"23","author":"Zamani","year":"2017","journal-title":"World J Gastroenterol"},{"key":"2025121510274989000_10.10.e037375.10","doi-asserted-by":"crossref","unstructured":"Grayson Lindsay M M , Crowe S , et al . Kucers' the use of antibiotics. 7 th ed. Boca Raton, Florida, America: CRC press, 2017: 3187\u201394.","DOI":"10.1201\/9781498747967"},{"key":"2025121510274989000_10.10.e037375.11","first-page":"1048","article-title":"Double-Blind short-term trial of furazolidone in peptic ulcer","volume":"1","author":"Zheng","year":"1985","journal-title":"Lancet"},{"key":"2025121510274989000_10.10.e037375.12","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.1.306-308.2001"},{"key":"2025121510274989000_10.10.e037375.13","first-page":"410","article-title":"Mutations in Helicobacter pylori porD and oorD genes may contribute to furazolidone resistance","volume":"47","author":"Su","year":"2006","journal-title":"Croat Med J"},{"key":"2025121510274989000_10.10.e037375.14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/1319-3767.91724","article-title":"Furazolidone in Helicobacter pylori therapy: misunderstood and often unfairly maligned drug told in a story of French bread","volume":"18","author":"Graham","year":"2012","journal-title":"Saudi J Gastroenterol"},{"key":"2025121510274989000_10.10.e037375.15","first-page":"191","article-title":"Studies on the effect of ascorbic acid and selenium on the genotoxicity of nitrofurans: nitrofurazone and furazolidone","volume":"232","author":"Gajewska","year":"1990","journal-title":"Mutat Res"},{"key":"2025121510274989000_10.10.e037375.16","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/ijc.2910480420","article-title":"Attenuating effect of the monoamine oxidase inhibitor furazolidone on the anti-carcinogenetic effect of cysteamine on gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats","volume":"48","author":"Tatsuta","year":"1991","journal-title":"Int J Cancer"},{"key":"2025121510274989000_10.10.e037375.17","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2036.2000.00709.x","article-title":"Furazolidone versus metronidazole in quadruple therapy for eradication of Helicobacter pylori in duodenal ulcer disease","volume":"14","author":"Malekzadeh","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121510274989000_10.10.e037375.18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700"},{"key":"2025121510274989000_10.10.e037375.19","unstructured":"ICH . Clinical safety data management: definitions and standards for Expedited reporting E2A 1994."},{"key":"2025121510274989000_10.10.e037375.20","first-page":"2786","article-title":"Comparison of 10-day and 14-day furazolidone-containing quadruple salvage therapies for Helicobacter pylori eradication","volume":"22","author":"Zheng","year":"2013","journal-title":"Chinese Journal of New Drugs"},{"key":"2025121510274989000_10.10.e037375.21","unstructured":"Medical dictionary for regulatory activities. Available: https:\/\/www.meddra.org [Accessed 21 July 2018]."},{"key":"2025121510274989000_10.10.e037375.22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"2025121510274989000_10.10.e037375.23","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"2025121510274989000_10.10.e037375.24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"2025121510274989000_10.10.e037375.25","doi-asserted-by":"publisher","DOI":"10.2307\/2533446"},{"key":"2025121510274989000_10.10.e037375.26","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2889"},{"key":"2025121510274989000_10.10.e037375.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.10.007"},{"key":"2025121510274989000_10.10.e037375.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.03.013"},{"key":"2025121510274989000_10.10.e037375.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.04.026"},{"key":"2025121510274989000_10.10.e037375.30","first-page":"589","article-title":"[Five-day rabeprazole-based triple therapy for helicobacter pylori infection]","volume":"29","author":"Wang","year":"2004","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"key":"2025121510274989000_10.10.e037375.31","first-page":"195","article-title":"A comparison between moderate- and high-dose furazolidone in triple regimens for Helicobacterpylori eradication in Iran","volume":"6","author":"Hosseini","year":"2014","journal-title":"Middle East J Dig Dis"},{"key":"2025121510274989000_10.10.e037375.32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.2007.00518.x"},{"key":"2025121510274989000_10.10.e037375.33","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12468","article-title":"Furazolidone treatment for Helicobacter Pylori infection: A systematic review and meta\u2010analysis","volume":"23","author":"Zhuge","year":"2018","journal-title":"Helicobacter"},{"key":"2025121510274989000_10.10.e037375.34","article-title":"IARC monographs on the identification of carcinogenic hazards to humans"},{"key":"2025121510274989000_10.10.e037375.35","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1007\/s10620-017-4628-5","article-title":"Furazolidone, an underutilized drug for H. pylori eradication: lessons from Iran","volume":"62","author":"Mohammadi","year":"2017","journal-title":"Dig Dis Sci"},{"key":"2025121510274989000_10.10.e037375.36","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.19283"},{"key":"2025121510274989000_10.10.e037375.37","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/BF00539620","article-title":"[Inhibition of monoamine oxidase by bacteriostatically active nitrofuran derivatives]","volume":"256","author":"Palm","year":"1967","journal-title":"Naunyn Schmiedebergs Arch Exp Pathol Pharmakol"},{"key":"2025121510274989000_10.10.e037375.38","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1590\/S1807-59322008000400024","article-title":"Furazolidone and serotonin syndrome: is there any association?","volume":"63","author":"Karamanakos","year":"2008","journal-title":"Clinics"},{"key":"2025121510274989000_10.10.e037375.39","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3109\/00365528909091336","article-title":"Adverse reactions to furazolidone and other drugs. A comparative review","volume":"169","author":"Altamirano","year":"1989","journal-title":"Scand J Gastroenterol Suppl"},{"key":"2025121510274989000_10.10.e037375.40","doi-asserted-by":"publisher","DOI":"10.1177\/004947558701700215"},{"key":"2025121510274989000_10.10.e037375.41","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.26.2.160"},{"key":"2025121510274989000_10.10.e037375.42","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.9.1864"},{"key":"2025121510274989000_10.10.e037375.43","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.11569\/wcjd.v24.i33.4484","article-title":"Furazolidone-based firstline therapy for Helicobacter pylori infection in China: a meta-analysis","volume":"24","author":"XJ","year":"2016","journal-title":"World Chinese Journal of Digestology"},{"key":"2025121510274989000_10.10.e037375.44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2007.05082.x"},{"key":"2025121510274989000_10.10.e037375.45","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1046\/j.1365-2036.1997.00166.x","article-title":"Low cure rate of Helicobacter pylori infection with omeprazole and furazolidone dual therapy for one week","volume":"11","author":"Van Zwet","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121510274989000_10.10.e037375.46","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00640.x"},{"key":"2025121510274989000_10.10.e037375.47","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01299.x"},{"key":"2025121510274989000_10.10.e037375.48","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-5378.2002.00087.x"},{"key":"2025121510274989000_10.10.e037375.49","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.02210.x"},{"key":"2025121510274989000_10.10.e037375.50","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12089"},{"key":"2025121510274989000_10.10.e037375.51","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00492.x"},{"key":"2025121510274989000_10.10.e037375.52","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00487.x"},{"key":"2025121510274989000_10.10.e037375.53","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.00895.x"},{"key":"2025121510274989000_10.10.e037375.54","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3748\/wjg.v10.i5.747","article-title":"Clinical evaluation of four one-week triple therapy regimens in eradicating Helicobacter pylori infection","volume":"10","author":"Guo","year":"2004","journal-title":"World J Gastroenterol"},{"key":"2025121510274989000_10.10.e037375.55","first-page":"1799","article-title":"Effectiveness of furazolidone-containing triple therapies with different courses of treatment for Helicobacter pylori infection","volume":"31","author":"Zhang","year":"2011","journal-title":"Chinese Journal of Hospital Pharmacy"},{"key":"2025121510274989000_10.10.e037375.56","first-page":"480","article-title":"Therapeutic effect of clarithromycin-based triple therapy for Helicobacter pylori eradication","volume":"17","author":"Zhang","year":"2012","journal-title":"Chinese Journal of Gastroenterology"},{"key":"2025121510274989000_10.10.e037375.57","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.11569\/wcjd.v21.i14.1366","article-title":"Furazolidone-based quadruple therapy as first-line treatment for Helicobacter pylori infection","volume":"21","author":"Chen","year":"2013","journal-title":"World Chinese Journal of Digestology"},{"key":"2025121510274989000_10.10.e037375.58","first-page":"673","article-title":"Radical curative efficacy of quadruple therapy containing probiotics on persistent Helicobacter pylori infection: an efficacy observation","volume":"25","author":"Li","year":"2013","journal-title":"Chinese Journal of Microecology"},{"key":"2025121510274989000_10.10.e037375.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.01.008"},{"key":"2025121510274989000_10.10.e037375.60","first-page":"3496","article-title":"[Efficacy of furazolidone-based quadruple therapy as rescue treatment for refractory Helicobacter pylori infection]","volume":"93","author":"Zheng","year":"2013","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"2025121510274989000_10.10.e037375.61","first-page":"695","article-title":"The efficacy of golden Bifidobacterium combined with quadruple therapy on Helicobacter pylori infection","volume":"30","author":"Ke","year":"2018","journal-title":"Chinese Journal of Microecology"},{"key":"2025121510274989000_10.10.e037375.62","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.00931.x"},{"key":"2025121510274989000_10.10.e037375.63","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000014408","article-title":"Comparison the cost-efficacy of furazolidone-based versus clarithromycin-based quadruple therapy in initial treatment of Helicobacter pylori infection in a variable clarithromycin drug-resistant region, a single-center, prospective, randomized, open-label study","volume":"98","author":"Yi","year":"2019","journal-title":"Medicine"},{"key":"2025121510274989000_10.10.e037375.64","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1111\/j.1440-1746.2007.05029.x","article-title":"One-Week versus two-week furazolidone-based quadruple therapy as the first-line treatment for Helicobacter pylori infection in Iran","volume":"22","author":"Daghaghzadeh","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"2025121510274989000_10.10.e037375.65","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3748\/wjg.15.860","article-title":"Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori","volume":"15","author":"Cheng","year":"2009","journal-title":"WJG"},{"key":"2025121510274989000_10.10.e037375.66","first-page":"796","article-title":"Efficacy of different terms and different drugs therpy for Helicobacter pylori eradication: a randmoized controlled trial","volume":"32","author":"Zhao","year":"2012","journal-title":"Chinese Journal of Practical Internal Medicine"},{"key":"2025121510274989000_10.10.e037375.67","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i32.11415"},{"key":"2025121510274989000_10.10.e037375.68","article-title":"Comparison of quadruple and triple furazolidone containing regimens on eradication of Helicobacter pylori","volume":"29","author":"Mokhtare","year":"2015","journal-title":"Med J Islam Repub Iran"},{"key":"2025121510274989000_10.10.e037375.69","doi-asserted-by":"crossref","first-page":"866","DOI":"10.11569\/wcjd.v23.i5.866","article-title":"Effects of pantoprazole combined with furazolidone in Helicobacter pylori eradication therapy","volume":"23","author":"Xu","year":"2015","journal-title":"World Chinese Journal of Digestology"},{"key":"2025121510274989000_10.10.e037375.70","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12496","article-title":"Furazolidone-containing triple and quadruple eradication therapy for initial treatment for Helicobacter pylori infection: a multicenter randomized controlled trial in China","volume":"23","author":"Xie","year":"2018","journal-title":"Helicobacter"},{"key":"2025121510274989000_10.10.e037375.71","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2036.2003.01393.x","article-title":"Once-Daily, low-cost, highly effective Helicobacter pylori treatment to family members of gastric cancer patients","volume":"17","author":"Coelho","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121510274989000_10.10.e037375.72","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2003.03058.x"},{"key":"2025121510274989000_10.10.e037375.73","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01822.x"},{"key":"2025121510274989000_10.10.e037375.74","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.04.022"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-037375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T18:28:01Z","timestamp":1765823281000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-037375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":74,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10,19]]},"published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1136\/bmjopen-2020-037375"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-037375","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}